Live
- Indian consulate launches helpline numbers for Indians
- SUCI to contest for Tirupati Assembly
- Hyderabad: Congress chants Ram, Ram; steals thunder from BJP
- VIT Engineering Entrance Exam (VITEEE) from today
- BJP demands removal of ‘biased’, ‘incompetent’ officers
- Hyderabad: 20 Congress MLAs in touch with BRS, claims KCR
- Prof Vani takes charge as Dean in SPMVV
- My Dear Donga: trailer get grand launched
- Supreme Court reserves verdict
- Poll battle begins
Zydus gets USFDA nod for Glipizide
Highlights
Zydus Gets USFDA Nod For Glipizide. Zydus Cadila said on Tuesday that it has received USFDA approval to market Glipizide tablets used for the treatment of diabetes in the US market. “Zydus Cadila has received tentative approval from the USFDA to market Glipizide extended release tablets in the strengths of 2.5 mg, 5 mg and 10 mg,” company said in a statement. Glipizide ER tablet has $90.1 million sales in 2014.
Hyderabad: Zydus Cadila said on Tuesday that it has received USFDA approval to market Glipizide tablets used for the treatment of diabetes in the US market. “Zydus Cadila has received tentative approval from the USFDA to market Glipizide extended release tablets in the strengths of 2.5 mg, 5 mg and 10 mg,” company said in a statement. Glipizide ER tablet has $90.1 million sales in 2014.
“The group now has 97 approvals and has so far filed 249 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-2004,” it added.
Next Story
ADVERTISEMENT
